{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T20:42:13Z","timestamp":1771706533392,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ncl.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T22:27:16Z","timestamp":1532989636000},"page":"501-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Benign Intracranial Tumors"],"prefix":"10.1016","volume":"36","author":[{"given":"Justin T.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl_5","key":"10.1016\/j.ncl.2018.04.007_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and\u00a0other central nervous system tumors diagnosed in the United States in 2009-2013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/jnnp.63.1.116","article-title":"Epidemiological study of primary intracranial tumours in elderly people","volume":"63","author":"Kuratsu","year":"1997","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"21","key":"10.1016\/j.ncl.2018.04.007_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/jnci\/djj411","article-title":"New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"98","author":"Neglia","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1212\/01.WNL.0000149766.65843.19","article-title":"Intracranial meningioma and ionizing radiation in medical and occupational settings","volume":"64","author":"Phillips","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.04.007_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.wneu.2016.09.094","article-title":"Radiation-induced meningiomas: an exhaustive review of the literature","volume":"97","author":"Yamanaka","year":"2017","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-008-9734-y","article-title":"Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas","volume":"92","author":"Sioka","year":"2009","journal-title":"J\u00a0Neurooncol"},{"issue":"12","key":"10.1016\/j.ncl.2018.04.007_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1212\/WNL.58.12.1849","article-title":"History of head trauma and risk of intracranial meningioma: population-based case-control study","volume":"58","author":"Phillips","year":"2002","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2018.04.007_bib8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0277-5379(91)90030-H","article-title":"Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics","volume":"27","author":"Huisman","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ncl.2018.04.007_bib9","series-title":"Al-Mefty's meningiomas","first-page":"399","article-title":"Chemotherapy for intracranial meningiomas","author":"Chamberlain","year":"2011"},{"issue":"19","key":"10.1016\/j.ncl.2018.04.007_bib10","doi-asserted-by":"crossref","first-page":"16981","DOI":"10.18632\/oncotarget.4858","article-title":"A\u00a0high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas","volume":"6","author":"Beauchamp","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-010-0339-x","article-title":"Meningiomas and neurofibromatosis","volume":"99","author":"Goutagny","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"Smith","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","article-title":"The neuroimaging and clinical spectrum of neurofibromatosis 2","volume":"38","author":"Mautner","year":"1996","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2005-837581","article-title":"Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients","volume":"36","author":"Ruggieri","year":"2005","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajmg.a.34376","article-title":"Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis","volume":"158A","author":"Smith","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cge.13013","article-title":"Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager","volume":"92","author":"Gripp","year":"2017","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib18","first-page":"1469","article-title":"Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation","volume":"125","author":"Mehta","year":"2016","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-015-1918-7","article-title":"Identification of a novel germline SMARCB1 nonsense mutation in a family manifesting both schwannomatosis and unilateral vestibular schwannoma","volume":"125","author":"Wu","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am J Med Genet Part A"},{"key":"10.1016\/j.ncl.2018.04.007_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2377-11-9","article-title":"SMARCB1\/INI1 germline mutations contribute to 10% of sporadic schwannomatosis","volume":"11","author":"Rousseau","year":"2011","journal-title":"BMC Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2018.04.007_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cancergen.2014.04.001","article-title":"SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors","volume":"207","author":"Smith","year":"2014","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000001129","article-title":"Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis","volume":"84","author":"Smith","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10048-015-0472-y","article-title":"A\u00a0heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening","volume":"17","author":"Gerkes","year":"2016","journal-title":"Neurogenetics"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/path.4427","article-title":"Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas","volume":"234","author":"Smith","year":"2014","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib27","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ncl.2018.04.007_bib28","series-title":"WHO classification of tumours of the central nervous system","first-page":"231","article-title":"Meningiomas","author":"Perry","year":"2016"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib29","first-page":"4","article-title":"Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review","volume":"122","author":"Rogers","year":"2015","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"issue":"6123","key":"10.1016\/j.ncl.2018.04.007_bib31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostrom","year":"2001","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ijrobp.2017.07.008","article-title":"Prospective, randomized study of radiation dose escalation with combined proton-photon therapy for benign meningiomas","volume":"99","author":"Sanford","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ncl.2018.04.007_bib37","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/cncr.11645","article-title":"Radiotherapy alone or after subtotal resection for benign skull base meningiomas","volume":"98","author":"Mendenhall","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00172765","article-title":"The role of radiotherapy in the treatment of subtotally resected benign meningiomas","volume":"13","author":"Miralbell","year":"1992","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00006123-199803000-00002","article-title":"Results of linear accelerator-based radiosurgery for intracranial meningiomas","volume":"42","author":"Hakim","year":"1998","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ijrobp.2017.01.004","article-title":"The risk of radiation-induced tumors or malignant transformation after single-fraction intracranial radiosurgery: results based on a 25-year experience","volume":"97","author":"Pollock","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00182088","article-title":"Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma","volume":"8","author":"Grunberg","year":"1990","journal-title":"J\u00a0Neurooncol"},{"issue":"34","key":"10.1016\/j.ncl.2018.04.007_bib43","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A\u00a0phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J\u00a0Neurooncol"},{"issue":"7","key":"10.1016\/j.ncl.2018.04.007_bib45","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J\u00a0Neurooncol"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/02688690400012392","article-title":"Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up","volume":"18","author":"Newton","year":"2004","journal-title":"Br J Neurosurg"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2018.04.007_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","article-title":"Non-resectable slow-growing meningiomas treated by hydroxyurea","volume":"67","author":"Loven","year":"2004","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/jocn.2001.1019","article-title":"Treatment of high risk or recurrent meningiomas with hydroxyurea","volume":"9","author":"Rosenthal","year":"2002","journal-title":"J\u00a0Clin Neurosci"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"suppl 5","key":"10.1016\/j.ncl.2018.04.007_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nou237.30","article-title":"Effects of everolimus on meningioma growth in patients with neurofibromatosis type 2","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ncl.2018.04.007_bib54","series-title":"WHO classification of tumours of the central nervous system","first-page":"214","article-title":"Schwannoma","author":"Antonescu","year":"2016"},{"issue":"5\u20136","key":"10.1016\/j.ncl.2018.04.007_bib55","first-page":"305","article-title":"Tumors of the central nervous system in biopsy and autopsy material. 7th communication: neurinomas and neurofibromatoses with CNS involvement","volume":"127","author":"Schneider","year":"1983","journal-title":"Zentralbl Allg Pathol"},{"key":"10.1016\/j.ncl.2018.04.007_bib56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.wneu.2017.05.066","article-title":"Radiation-induced schwannomas and neurofibromas: a systematic review","volume":"104","author":"Yamanaka","year":"2017","journal-title":"World Neurosurg"},{"issue":"304","key":"10.1016\/j.ncl.2018.04.007_bib57","first-page":"603","article-title":"A\u00a0clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q\u00a0J Med"},{"issue":"11","key":"10.1016\/j.ncl.2018.04.007_bib58","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2018.04.007_bib59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: a retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","article-title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis","volume":"88","author":"Smith","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3171\/2015.3.SPINE141145","article-title":"Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis type 2: a retrospective study at a single institution","volume":"24","author":"Li","year":"2016","journal-title":"J\u00a0Neurosurg Spine"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00000478-199003000-00002","article-title":"Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome","volume":"14","author":"Carney","year":"1990","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.endinu.2017.09.006","article-title":"Carney complex review: genetic features","volume":"65","author":"Bosco Schamun","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/neuros\/nyx368","article-title":"Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient","volume":"83","author":"King","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ncl.2018.04.007_bib65","series-title":"WHO classification of tumours of the central nervous system","first-page":"219","article-title":"Neurofibroma","author":"Perry","year":"2016"},{"issue":"10","key":"10.1016\/j.ncl.2018.04.007_bib66","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/PAS.0b013e3181accc6c","article-title":"Hybrid schwannoma\/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors","volume":"33","author":"Hornick","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ncl.2018.04.007_bib67","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/1097-0142(19950301)75:5<1109::AID-CNCR2820750510>3.0.CO;2-M","article-title":"Cellular schwannoma. A clinicopathologic, DNA flow cytometric, and proliferation marker study of 70 patients","volume":"75","author":"Casadei","year":"1995","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib68","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/1097-0142(19900915)66:6<1266::AID-CNCR2820660628>3.0.CO;2-E","article-title":"Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors","volume":"66","author":"White","year":"1990","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib69","first-page":"1649","article-title":"Universal absence of merlin, but not other ERM family members, in schwannomas","volume":"151","author":"Stemmer-Rachamimov","year":"1997","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.ncl.2018.04.007_bib70","first-page":"911","article-title":"Genetic landscape of sporadic vestibular schwannoma","volume":"128","author":"H\u00e5vik","year":"2018","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib71","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/nou317","article-title":"Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas","volume":"17","author":"Dewan","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/humu.20679","article-title":"Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas","volume":"29","author":"Sestini","year":"2008","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.ncl.2018.04.007_bib73","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/ng.3688","article-title":"The genomic landscape of schwannoma","volume":"48","author":"Agnihotri","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ncl.2018.04.007_bib74","first-page":"30","article-title":"Incidence and growth pattern of vestibular schwannomas in a Danish county, 1977-98","volume":"543","author":"Mirz","year":"2000","journal-title":"Acta Otolaryngol Suppl"},{"issue":"1","key":"10.1016\/j.ncl.2018.04.007_bib75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1227\/NEU.0000000000001414","article-title":"Ten-year follow-up on tumor growth and hearing in patients observed with an intracanalicular vestibular schwannoma","volume":"80","author":"Kirchmann","year":"2017","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib76","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/019459980112400609","article-title":"Long-term results of the first 500 cases of acoustic neuroma surgery","volume":"124","author":"Wiet","year":"2001","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib77","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006123-199704000-00007","article-title":"Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2","volume":"40","author":"Samii","year":"1997","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijrobp.2017.09.024","article-title":"Population-based study of stereotactic radiosurgery or fractionated stereotactic radiation therapy for vestibular schwannoma: long-term outcomes and toxicities","volume":"100","author":"Lo","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ncl.2018.04.007_bib79","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"4","key":"10.1016\/j.ncl.2018.04.007_bib80","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ncl.2018.04.007_bib81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"7","key":"10.1016\/j.ncl.2018.04.007_bib82","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"9","key":"10.1016\/j.ncl.2018.04.007_bib83","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.ncl.2018.04.007_bib84","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MAO.0000000000001180","article-title":"Correlation between aspirin intake and reduced growth of human vestibular schwannoma: volumetric analysis","volume":"37","author":"Kandathil","year":"2016","journal-title":"Otol Neurotol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T01:29:44Z","timestamp":1604712584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918312040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0733861918312040"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.04.007","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benign Intracranial Tumors","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}